Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time

IF 4.6 2区医学 Q2 IMMUNOLOGY

Clinical & Translational Immunology Pub Date : 2022-04-18 DOI:10.1002/cti2.1388

Sebastian Havervall, Ulrika Marking, Nina Greilert-Norin, Max Gordon, Henry Ng, Wanda Christ, Mia Phillipson, Peter Nilsson, Sophia Hober, Kim Blom, Jonas Klingstr?m, Sara Mangsbo, Mikael ?berg, Charlotte Th?lin

{"title":"Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time","authors":"Sebastian Havervall, Ulrika Marking, Nina Greilert-Norin, Max Gordon, Henry Ng, Wanda Christ, Mia Phillipson, Peter Nilsson, Sophia Hober, Kim Blom, Jonas Klingstr?m, Sara Mangsbo, Mikael ?berg, Charlotte Th?lin","doi":"10.1002/cti2.1388","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>To determine the long-term impact of prior SARS-CoV-2 infection on immune responses after COVID-19 vaccination.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Using longitudinally collected blood samples from the COMMUNITY study, we determined binding (WHO BAU mL<sup>−1</sup>) and neutralising antibody titres against ten SARS-CoV-2 variants over 7 months following BNT162b2 in SARS-CoV-2-recovered (<i>n</i> = 118) and SARS-CoV-2-naïve (<i>n</i> = 289) healthcare workers with confirmed prior SARS-CoV-2 infection. A smaller group with (<i>n</i> = 47) and without (<i>n</i> = 60) confirmed prior SARS-CoV-2 infection receiving ChAdOx1 nCoV-19 was followed for 3 months. SARS-CoV-2-specific memory T-cell responses were investigated in a subset of SARS-CoV-2-naïve and SARS-CoV-2-recovered vaccinees.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Vaccination with both vaccine platforms resulted in substantially enhanced T-cell responses, anti-spike IgG responses and neutralising antibodies effective against ten SARS-CoV-2 variants in SARS-CoV-2-recovered participants as compared to SARS-CoV-2-naïve participants. The enhanced immune responses sustained over 7 months following vaccination.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>These findings imply that prior SARS-CoV-2 infection should be taken into consideration when planning booster doses and design of current and future COVID-19 vaccine programmes.</p>\n </section>\n </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"11 4","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2022-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.1388","citationCount":"20","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Immunology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cti2.1388","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 20

Abstract

Objective

To determine the long-term impact of prior SARS-CoV-2 infection on immune responses after COVID-19 vaccination.

Methods

Using longitudinally collected blood samples from the COMMUNITY study, we determined binding (WHO BAU mL⁻¹) and neutralising antibody titres against ten SARS-CoV-2 variants over 7 months following BNT162b2 in SARS-CoV-2-recovered (n = 118) and SARS-CoV-2-naïve (n = 289) healthcare workers with confirmed prior SARS-CoV-2 infection. A smaller group with (n = 47) and without (n = 60) confirmed prior SARS-CoV-2 infection receiving ChAdOx1 nCoV-19 was followed for 3 months. SARS-CoV-2-specific memory T-cell responses were investigated in a subset of SARS-CoV-2-naïve and SARS-CoV-2-recovered vaccinees.

Results

Vaccination with both vaccine platforms resulted in substantially enhanced T-cell responses, anti-spike IgG responses and neutralising antibodies effective against ten SARS-CoV-2 variants in SARS-CoV-2-recovered participants as compared to SARS-CoV-2-naïve participants. The enhanced immune responses sustained over 7 months following vaccination.

Conclusion

These findings imply that prior SARS-CoV-2 infection should be taken into consideration when planning booster doses and design of current and future COVID-19 vaccine programmes.

Abstract Image

查看原文本刊更多论文

SARS-CoV-2感染对疫苗诱导的免疫反应的影响

目的探讨既往SARS-CoV-2感染对接种COVID-19疫苗后免疫应答的长期影响。方法利用从COMMUNITY研究中纵向采集的血液样本，在确诊感染SARS-CoV-2的SARS-CoV-2康复(n = 118)和SARS-CoV-2-naïve (n = 289)卫生保健工作者中检测BNT162b2后7个月内针对10种SARS-CoV-2变异的结合抗体(WHO BAU mL - 1)和中和抗体滴度。另一组确诊为SARS-CoV-2感染的患者(n = 47)和未确诊为SARS-CoV-2感染的患者(n = 60)接受ChAdOx1 nCoV-19治疗，随访3个月。在SARS-CoV-2-naïve和sars - cov -2恢复疫苗的一个子集中研究了sars - cov -2特异性记忆t细胞反应。结果与SARS-CoV-2-naïve参与者相比，接种这两种疫苗平台可显著增强SARS-CoV-2康复参与者的t细胞应答、抗刺突IgG应答和对10种SARS-CoV-2变体有效的中和抗体。增强的免疫反应在接种疫苗后持续了7个多月。结论这些发现提示在规划加强剂量和设计当前和未来的COVID-19疫苗规划时应考虑既往的SARS-CoV-2感染情况。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Immunology Medicine-Immunology and Allergy

CiteScore

12.00

自引率

1.70%

发文量

审稿时长

13 weeks

期刊介绍： Clinical & Translational Immunology is an open access, fully peer-reviewed journal devoted to publishing cutting-edge advances in biomedical research for scientists and physicians. The Journal covers fields including cancer biology, cardiovascular research, gene therapy, immunology, vaccine development and disease pathogenesis and therapy at the earliest phases of investigation.